Research | OneLook Acronym Finder |
Serial Number | 90401414 |
Registration Number | 6761734 |
Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
Attorney Name | Yi Wan |
Attorney Docket Number | CQZ0122111 |
2020-12-22 | Application Filed |
2020-12-25 | Location: NEW APPLICATION PROCESSING |
2020-12-25 | Status: Live/Pending |
2020-12-25 | Transaction Date |
2022-06-14 | Trademark Registered |
Owner: | Nanjing Nutrabuilding Bio-tech Co., Ltd. |
Entity Statement | limited company (ltd.) |
Address | Room 1805, Building 1, No. 270 Jiqingmen Nanjing, Jiangsu CN 210017 |
Legal Entity Type | |
Legal Entity State | CN |
Owner: | Ingredientology Inside, LLC |
Address | 7700 Windrose Ave Ste G300 Plano TX 75024 |
Legal Entity Type | Limited Liability Company |
Legal Entity State | CN |
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
International Codes: | 1 |
U.S. Codes: | 001,005,006,010,026,046 |
Type Code | Type |
---|---|
GS0011 | Beta-Nicotinamide Mononucleotide and mixtures containing Beta-Nicotinamide Mononucleotide, used as raw ingredients for the manufacture of foods and nutritional and dietary supplements; Derivatives of Beta-Nicotinamide Mononucleotide including salts, polymers, esters, and acids, and mixtures containing derivatives of Beta-Nicotinamide Mononucleotide, used as raw ingredients for the manufacture of foods and nutritional and dietary supplements; Beta-Nicotinamide Mononucleotide isomers and mixtures containing Beta-Nicotinamide Mononucleotide isomers, used as raw ingredients for the manufacture of foods and nutritional and dietary supplements; derivatives of Beta-Nicotinamide Mononucleotide isomers including salts, polymers, esters, and acids, and mixtures containing derivatives of Beta-Nicotinamide Mononucleotide isomers, used as raw ingredients for the manufacture of foods and nutritional and dietary supplements |
GS0011 | Beta-Nicotinamide Mononucleotide and mixtures containing Beta-Nicotinamide Mononucleotide, used as raw ingredients for the manufacture of foods and nutritional and dietary supplements; Derivatives of Beta-Nicotinamide Mononucleotide including salts, polymers, esters, and acids, and mixtures containing derivatives of Beta-Nicotinamide Mononucleotide, used as raw ingredients for the manufacture of foods and nutritional and dietary supplements; Beta-Nicotinamide Mononucleotide isomers and mixtures containing Beta-Nicotinamide Mononucleotide isomers, used as raw ingredients for the manufacture of foods and nutritional and dietary supplements; derivatives of Beta-Nicotinamide Mononucleotide isomers including salts, polymers, esters, and acids, and mixtures containing derivatives of Beta-Nicotinamide Mononucleotide isomers, used as raw ingredients for the manufacture of foods and nutritional and dietary supplements |
Description | Date | Event Coding |
---|---|---|
NEW APPLICATION ENTERED IN TRAM | 2020-12-25 | 1 NWAP I:Incoming Correspondence |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2021-03-08 | 2 NWOS I:Incoming Correspondence |
ASSIGNED TO EXAMINER | 2021-04-29 | 3 DOCK D:Assigned to Examiner |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2021-05-03 | 4 CNSA P: |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2021-05-19 | 5 NONP E:E-Mail |
PUBLISHED FOR OPPOSITION | 2021-06-08 | 6 PUBO A:Allowance for Publication |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2021-06-08 | 7 NPUB E:E-Mail |
NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2021-08-03 | 8 NOAM E:E-Mail |
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2021-10-27 | 9 REAP I:Incoming Correspondence |
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2021-10-27 | 10 ARAA I:Incoming Correspondence |
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | 2021-10-27 | 11 EWAF I:Incoming Correspondence |
TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2021-10-27 | 12 TCCA I:Incoming Correspondence |
TEAS STATEMENT OF USE RECEIVED | 2021-11-02 | 13 EISU I:Incoming Correspondence |
CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2021-11-26 | 14 AITU A:Allowance for Publication |
USE AMENDMENT FILED | 2021-11-02 | 15 IUAF S: |
STATEMENT OF USE PROCESSING COMPLETE | 2021-11-29 | 16 SUPC I:Incoming Correspondence |
ASSIGNED TO EXAMINER | 2021-11-30 | 17 DOCK D:Assigned to Examiner |
SU - NON-FINAL ACTION - WRITTEN | 2021-12-01 | 18 CNRT W: |
NON-FINAL ACTION E-MAILED | 2021-12-01 | 19 GNRT F:First Action |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2021-12-01 | 20 GNRN O:Outgoing Correspondence |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2022-05-11 | 21 TROA I:Incoming Correspondence |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2022-05-11 | 22 CRFA I:Incoming Correspondence |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2022-05-11 | 23 TEME I:Incoming Correspondence |
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2022-05-12 | 24 CNPR P: |
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2022-05-13 | 25 SUNA E:E-Mail |
REGISTERED-PRINCIPAL REGISTER | 2022-06-14 | 26 R.PR A:Allowance for Publication |
NOTICE OF REGISTRATION CONFIRMATION EMAILED | 2022-06-14 | 27 NRCC E:E-Mail |
TEAS WITHDRAWAL OF ATTORNEY RECEIVED | 2023-03-28 | 28 WOAR I:Incoming Correspondence |
WITHDRAWAL OF ATTORNEY GRANTED | 2023-03-28 | 29 WOAG I:Incoming Correspondence |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.